Table 4 Prognosis of SCCC in past studies and the present study
study | FIGO | n | survival | Treatment |
|---|---|---|---|---|
Lee et al. (2008) [8] | IB-IIA | 24 | 5y OS: 53% | Ope + chemo |
IB-IIA | 24 | 5y OS:46% | Ope + CCRT | |
Kuji et al. (2013) [9] | IB-IIB | 7 | 4y OS: 29% | Ope ± RT |
IB-IIB | 21 | 4y OS: 65% | Ope ± CCRT or chemo | |
Zivanovic et al. (2009) [10] | IA2-IB2 | 6 | 3y OS: 83% | CCRT |
Hoskins et al. (2003) [11] | I-IIA | 16 | 3y PFS: 80% | CCRT±chemo |
Present study | I-IIA (all) | 23 | 5y OS: 60% | |
I-IIA (SCC) | 10 | 5y OS: 53% | ||
IIB-IVA (all) | 34 | 5y OS: 50% | ||
IIB-IVA (SCC) | 19 | 5y OS: 78% |